3 Reasons Why Investors Undervalue Allergan
November 30, 2015 at 14:55 PM EST
Are investors undervaluing Allergan (AGN)? That’s the opinion of Normura analyst Shibani Malhotra in a research note published earlier today in which she argues that at its current price of $315 a share, the drug maker trades roughly 15% below the implied per-share value of its $150 billion merger deal with Pfizer (PFE). What are […]